Background
• Inflammatory bowel diseases (IBD), represented by Ulcerative Colitis (UC) and Crohn's disease (CD), are associated with significant morbidity, impact on quality of life and large therapeutic unmet medical need. The treatment options for IBD have improved significantly in the last twenty years due to, among others, the availability of new biological agents [1, 2] . • Data on biologic treatment persistence and switching in German patients with IBD as well as disease specific cost data, especially in large population based studies, are sparse.
• Treatment groups were defined as follows: 1. All IBD patients initiating treatment with VDZ (ATC-code L04AA33), either biologic treatment naïve or switching from an anti-TNFα 2. All IBD patients initiating treatment with an anti-TNFα (adalimumab, golimumab, infliximab; ATC codes L04AB04, L04AB06, L04AB02), either biologic treatment naïve or switching from another anti-TNFα • Observation started with the first prescription in this period. First observed treatment discontinuation and switching to another biologic were compared between anti-TNFα and VDZ patients, both unadjusted by means of log-rank tests and adjusted for age and gender by multivariable cox proportional hazards models. A switch was assumed if at least one prescription of another biologic was observed; discontinuation was defined as no further prescription of any biologic agent >90 days after the last prescription. • Drug costs, based on pharmacy retail prices (exclusive individual discounts; [3] ), were reported per observed patient month for periods of continuous index treatment.
Conclusions
• This is the first study reporting rates of treatment discontinuation and switching as well as drug related costs for German IBD patients treated with biologics based on a large, representative claims database. • In contrast to previous observational evidence (>75-80% [4] [5] [6] [7] ), less than two-thirds of IBD patients continued treatment with a biologic agent after 12 months. • Lower medication costs have been reported in the literature, as the share of biologic patients used to be lower in these studies and biologics are in general the main cost driver [8, 9] . • There is a tendency towards a longer duration on therapy in VDZ patients, with comparable drug costs. • Analysis of the full dataset including 1,149 patients will provide more detail, especially for subgroups (UC vs. CD and bio-naïve vs. bio-experienced).
• The main objectives of this interim analysis were to describe rates of biologic treatment switching and discontinuation for patients who initiated treatment on anti-TNFα antibodies (adalimumab, golimumab, infliximab) and vedolizumab (VDZ) in IBD patients and to report associated drug costs.
Results

Strengths and Limitations
• The used claims data cover a patient population of 7.5 million insured persons, about 10.5% of the statutorily insured population in Germany. • Claims data in general are less prone to selection bias or cluster effects that may influence study results. • Due to the fact that retrospective claims data were analyzed, specific patient parameters are not available (e.g. laboratory results or patient-reported-outcomes), since these data do not have any effect on the financial reimbursement for the sickness fund. • As cases are not randomized to each cohort but follow a sequential treatment pathway, systematic baseline differences between the treatment cohorts are likely. Furthermore, treatments may be dictated by individual patient profile, which is characterized by variables that cannot be observed in claims data. female gender was associated with earlier treatment discontinuation and switch (HR=1.490; 95% CI: 1.139-1.949), whereas VDZ vs. anti-TNFα as index treatment was associated with later discontinuation and switch (HR=0.692; 95% CI: 0.480-0.998), higher age was only slightly associated with earlier treatment discontinuation and switch (HR=1.008; 95% CI: 0.999-1.017).
Figure 3: Results from the cox proportional hazards model
The variables prior biologic treatment, IBD type, IBD complications and CCI were excluded from the model because of insignificance (p>0.100)
• Figure 2 displays the 12-month treatment continuation as Kaplan-Meier-curve. 59.4% vs. 67.6% (p=0.060) continued treatment after 12 months. 2 patients in each treatment group continued their index treatment until they died within the observational period.
• Patients with anti-TNFα were younger than patients with VDZ (mean age 37.2 vs. 40.5 years), had less comorbidities and IBDrelated complications (CCI 0.89 vs. 1.07, 16.8% vs. 25.2% with complications; table 1). • The proportion of CD-patients was higher in the anti-TNFα group (56.2% vs. 46.7%; table 1). • Only one-fifth of the VDZ patients was biologics-naïve whereas four-fifths of the anti-TNFα patients had no prior experiences with biologics (table 1) .
• Prior biologic treatment, IBD type (CD vs. UC vs. unspecified), the presence of IBD complications and general comorbidity had no significant impact ( figure 3 ).
